We are live on ! Find out more
DnB Asset Management

DnB Asset Management Portfolio holdings

AUM $28B
1-Year Est. Return 26%
This Fund
S&P 500
This Quarter Est. Return
+3.33%
1 Year Est. Return
+26%
3 Year Est. Return
+97.1%
5 Year Est. Return
+115.87%
10 Year Est. Return
+443.63%
AUM
$28.7B
AUM Growth
+$1.92B
Cap. Flow
+$1.12B
Cap. Flow %
3.92%
Top 10 Hldgs %
44.24%
Holding
782
New
51
Increased
433
Reduced
192
Closed
51

Top Buys

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$467M
2
V icon
Visa
V
+$259M
3
MA icon
Mastercard
MA
+$206M
4
HPQ icon
HP
HPQ
+$191M
5
TEAM icon
Atlassian
TEAM
+$186M

Sector Composition

Rank Sector Weight
1 Technology 39.4%
2 Communication Services 14.24%
3 Financials 14%
4 Consumer Discretionary 10.61%
5 Healthcare 7.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ERII icon
676
Energy Recovery
ERII
$410M
$515K ﹤0.01%
38,196
MTN icon
677
Vail Resorts
MTN
$5.23B
$509K ﹤0.01%
+3,836
New +$565K
STEM icon
678
Stem
STEM
$48.3M
$489K ﹤0.01%
+32,461
New +$622K
IMVT icon
679
Immunovant
IMVT
$8.14B
$460K ﹤0.01%
18,109
+5,701
+46% +$127K
CLDX icon
680
Celldex Therapeutics
CLDX
$3.34B
$459K ﹤0.01%
16,901
+3,650
+28% +$96.1K
IMCR icon
681
Immunocore
IMCR
$1.73B
$454K ﹤0.01%
13,066
+4,950
+61% +$175K
SIDU icon
682
Sidus Space
SIDU
$230M
$442K ﹤0.01%
+140,634
New +$162K
APGE icon
683
Apogee Therapeutics
APGE
$10.2B
$436K ﹤0.01%
+5,775
New +$364K
EVLV icon
684
Evolv Technologies
EVLV
$1.06B
$407K ﹤0.01%
+56,877
New +$404K
URGN icon
685
UroGen Pharma
URGN
$2.25B
$397K ﹤0.01%
+16,961
New +$368K
ACAD icon
686
Acadia Pharmaceuticals
ACAD
$5.05B
$393K ﹤0.01%
14,702
+1,525
+12% +$36.4K
BVN icon
687
Compañía de Minas Buenaventura
BVN
$8.76B
$392K ﹤0.01%
14,089
TAL icon
688
TAL Education Group
TAL
$6.95B
$385K ﹤0.01%
35,263
HIMS icon
689
Hims & Hers Health
HIMS
$7.35B
$382K ﹤0.01%
11,770
+3,886
+49% +$166K
RGNX icon
690
Regenxbio
RGNX
$690M
$369K ﹤0.01%
25,612
+7,689
+43% +$95.8K
FTAI icon
691
FTAI Aviation
FTAI
$22.3B
$349K ﹤0.01%
1,774
STNE icon
692
StoneCo
STNE
$2.54B
$349K ﹤0.01%
23,609
-32,587
-58% -$545K
UPB
693
Upstream Bio Inc
UPB
$408M
$347K ﹤0.01%
+12,793
New +$318K
CNTA
694
DELISTED
Centessa Pharmaceuticals
CNTA
$319K ﹤0.01%
12,746
+3,758
+42% +$95.2K
SGI
695
Somnigroup International
SGI
$13.4B
$315K ﹤0.01%
3,523
+449
+15% +$39.2K
AS icon
696
Amer Sports
AS
$21.2B
$311K ﹤0.01%
+8,315
New +$285K
CALY
697
Callaway Golf Company
CALY
$3.08B
$308K ﹤0.01%
+26,416
New +$279K
LENZ
698
LENZ Therapeutics
LENZ
$167M
$307K ﹤0.01%
+19,163
New +$559K
FDS icon
699
Factset
FDS
$10.2B
$295K ﹤0.01%
1,015
-5,880
-85% -$1.65M
USFD icon
700
US Foods
USFD
$23.8B
$287K ﹤0.01%
3,811
-20,599
-84% -$1.55M

Similar funds

DnB Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, DnB Asset Management held 782 positions worth $28.7B, up 7.2% from $26.7B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

DnB Asset Management deployed $1.12B of net new capital in Q4 2025, opening 51 new positions and adding to 433 existing holdings. Its largest new stake was Petrobras: 1,837,813 shares worth $21.8M.

By sector, the portfolio is most concentrated in Technology at 39% of assets, down from 42% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $356M trimmed.

  • DnB Asset Management's largest Q4 2025 buy was Petrobras: 1,837,813 shares worth $21.8M.
  • DnB Asset Management added most to Meta Platforms (Facebook) in Q4 2025, an estimated $467M increase.
  • DnB Asset Management's biggest Q4 2025 reduction was Alphabet (Google) Class A, cutting an estimated $356M.
  • DnB Asset Management fully exited MasTec in Q4 2025, selling an estimated $59.7M.
  • DnB Asset Management's ten largest holdings make up 44% of its $28.7B portfolio in Q4 2025.
  • DnB Asset Management opened 51 new positions and closed 51 in Q4 2025.
  • DnB Asset Management's portfolio value rose 7.2% quarter-over-quarter to $28.7B.

Based on DnB Asset Management's 13F filing for Q4 2025, filed 5 Feb 2026.